Date:
May 06, 2026
Content:
The U.S. Food and Drug Administration (FDA) has released a Form 483 inspection record for Ajinomoto Company Inc., a manufacturing facility located in Japan. This release follows an inspection conducted by the agency in early 2025.
The Form 483 document highlights specific observations made by FDA investigators during their visit to the site. These reports are typically issued when investigators identify potential violations of the Food, Drug, and Cosmetic Act or related regulatory standards. It serves as a formal notice for the company to address and rectify any highlighted concerns regarding their manufacturing processes.
As part of the FDA’s oversight of international drug and ingredient production, these records provide transparency into the quality and safety standards maintained by global suppliers. Companies receiving a Form 483 are expected to respond with a corrective action plan to ensure ongoing compliance with U.S. regulations.
Source: FDA Electronic Reading Room
Link:
http://www.fda.gov/drugs/cder-foia-electronic-reading-room/ajinomoto-company-inc-02212025
Keywords:
FDA, Ajinomoto Company Inc, Japan, Form 483, Drug Manufacturing, Inspection Report, Regulatory Compliance